These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 16136026)

  • 1. Ten years of marketing approvals of anticancer drugs in Europe: regulatory policy and guidance documents need to find a balance between different pressures.
    Apolone G; Joppi R; Bertele' V; Garattini S
    Br J Cancer; 2005 Sep; 93(5):504-9. PubMed ID: 16136026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medicines for children licensed by the European Agency for the Evaluation of Medicinal Products.
    Ceci A; Felisi M; Catapano M; Baiardi P; Cipollina L; Ravera S; Bagnulo S; Reggio S; Rondini G
    Eur J Clin Pharmacol; 2002 Nov; 58(8):495-500. PubMed ID: 12451425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Post-marketing research and its outcome for novel anticancer agents approved by both the FDA and EMA between 2005 and 2010: A cross-sectional study.
    Zeitoun JD; Baron G; Vivot A; Atal I; Downing NS; Ross JS; Ravaud P
    Int J Cancer; 2018 Jan; 142(2):414-423. PubMed ID: 28929484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Haematological anticancer drugs in Europe: any added value at the time of approval?
    Bertele' V; Banzi R; Capasso F; Tafuri G; Trotta F; Apolone G; Garattini S
    Eur J Clin Pharmacol; 2007 Jul; 63(7):713-9. PubMed ID: 17530236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Approval of Cancer Drugs With Uncertain Therapeutic Value: A Comparison of Regulatory Decisions in Europe and the United States.
    Salcher-Konrad M; Naci H; Davis C
    Milbank Q; 2020 Dec; 98(4):1219-1256. PubMed ID: 33021339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic indications in oncology: emerging features and regulatory dynamics.
    Tafuri G; Leufkens HG; Laing R; Trotta F
    Eur J Cancer; 2010 Feb; 46(3):471-5. PubMed ID: 20056536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Qualitative Study on the Differences Between Trial Populations and the Approved Therapeutic Indications of Antineoplastic Agents by 3 Regulatory Agencies From 2010 to 2018.
    Sumi E; Asada R; Lu Y; Ito-Ihara T; Grimes KV
    Clin Ther; 2020 Feb; 42(2):305-320.e0. PubMed ID: 32008723
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medicines for children licensed by the European Medicines Agency (EMEA): the balance after 10 years.
    Ceci A; Felisi M; Baiardi P; Bonifazi F; Catapano M; Giaquinto C; Nicolosi A; Sturkenboom M; Neubert A; Wong I
    Eur J Clin Pharmacol; 2006 Nov; 62(11):947-52. PubMed ID: 17021892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oblimersen: Augmerosen, BCL-2 antisense oligonucleotide - Genta, G 3139, GC 3139, oblimersen sodium.
    Drugs R D; 2007; 8(5):321-34. PubMed ID: 17767397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Continued cancer drug approvals in Japan and Europe after market withdrawal in the United States: A comparative study of accelerated approvals.
    Hakariya H; Moriarty F; Ozaki A; Mulinari S; Saito H; Tanimoto T
    Clin Transl Sci; 2024 Jul; 17(7):e13879. PubMed ID: 38987923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single-Arm Clinical Trials as Pivotal Evidence for Cancer Drug Approval: A Retrospective Cohort Study of Centralized European Marketing Authorizations Between 2010 and 2019.
    Tenhunen O; Lasch F; Schiel A; Turpeinen M
    Clin Pharmacol Ther; 2020 Sep; 108(3):653-660. PubMed ID: 32578196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of Surrogate End Point Trends in Clinical Trials to Approve Oncology Drugs From 2001 to 2020 in Japan.
    Maeda H; Shingai R; Takeda K; Hara A; Murai Y; Ofuchi M
    JAMA Netw Open; 2023 Apr; 6(4):e238875. PubMed ID: 37115550
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical trials for registration in the European Union: the EMEA 5-year experience in oncology.
    Pignatti F; Aronsson B; Vamvakas S; Wade G; Papadouli I; Papaluca M; Moulon I; Le Courtois P
    Crit Rev Oncol Hematol; 2002 May; 42(2):123-35. PubMed ID: 12007970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval.
    Gyawali B; Hey SP; Kesselheim AS
    JAMA Intern Med; 2019 Jul; 179(7):906-913. PubMed ID: 31135808
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acceptance of surrogate end points in clinical trials supporting approval of drugs for cancer treatment by the Japanese regulatory agency.
    Maeda H; Kurokawa T
    Ann Oncol; 2015 Jan; 26(1):211-216. PubMed ID: 25361994
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anticancer Drug Development: The Way Forward.
    Connors T
    Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Erlotinib: CP 358774, NSC 718781, OSI 774, R 1415.
    Adis International Ltd
    Drugs R D; 2003; 4(4):243-8. PubMed ID: 12848590
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design characteristics, risk of bias, and reporting of randomised controlled trials supporting approvals of cancer drugs by European Medicines Agency, 2014-16: cross sectional analysis.
    Naci H; Davis C; Savović J; Higgins JPT; Sterne JAC; Gyawali B; Romo-Sandoval X; Handley N; Booth CM
    BMJ; 2019 Sep; 366():l5221. PubMed ID: 31533922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of validated and nonvalidated surrogate endpoints in two European Medicines Agency expedited approval pathways: A cross-sectional study of products authorised 2011-2018.
    Schuster Bruce C; Brhlikova P; Heath J; McGettigan P
    PLoS Med; 2019 Sep; 16(9):e1002873. PubMed ID: 31504034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of Control Arm Quality in Randomized Clinical Trials Leading to Anticancer Drug Approval by the US Food and Drug Administration.
    Hilal T; Sonbol MB; Prasad V
    JAMA Oncol; 2019 Jun; 5(6):887-892. PubMed ID: 31046071
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.